Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC

Among patients with EGFR -mutated lung cancer after chemoradiotherapy, 65% of patients who received osimertinib were alive without progression at 2 years, as compared with 13% of those who received placebo.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2024-08, Vol.391 (7), p.585-597
Hauptverfasser:	Lu, Shun, Kato, Terufumi, Dong, Xiaorong, Ahn, Myung-Ju, Quang, Le-Van, Soparattanapaisarn, Nopadol, Inoue, Takako, Wang, Chih-Liang, Huang, Meijuan, Yang, James Chih-Hsin, Cobo, Manuel, Özgüroğlu, Mustafa, Casarini, Ignacio, Khiem, Dang-Van, Sriuranpong, Virote, Cronemberger, Eduardo, Takahashi, Toshiaki, Runglodvatana, Yotsawaj, Chen, Ming, Huang, Xiangning, Grainger, Ellie, Ghiorghiu, Dana, van der Gronde, Toon, Ramalingam, Suresh S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Acrylamides - adverse effects Acrylamides - therapeutic use Adult Aged Aged, 80 and over Aniline Compounds - adverse effects Aniline Compounds - therapeutic use Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Cancer therapies Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - pathology Carcinoma, Non-Small-Cell Lung - therapy Chemoradiotherapy Chemoradiotherapy - adverse effects Chemoradiotherapy - methods Chemotherapy Critical Care Critical Care General Double-Blind Method Epidermal growth factor receptors ErbB Receptors - antagonists & inhibitors ErbB Receptors - genetics Female Hematology Humans Indoles International organizations Kaplan-Meier Estimate Lung Cancer Lung Neoplasms - genetics Lung Neoplasms - mortality Lung Neoplasms - pathology Lung Neoplasms - therapy Magnetic resonance imaging Male Metastasis Middle Aged Mutation Neoplasm Staging Non-small cell lung carcinoma Oncology Placebos Pneumonitis Progression-Free Survival Pulmonary Pyrimidines Radiation therapy Small cell lung carcinoma Statistical analysis Targeted cancer therapy Treatments in Oncology Tumors Tyrosine Kinase Inhibitors - adverse effects Tyrosine Kinase Inhibitors - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Among patients with EGFR -mutated lung cancer after chemoradiotherapy, 65% of patients who received osimertinib were alive without progression at 2 years, as compared with 13% of those who received placebo.
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa2402614